Literature DB >> 10096387

Long-term effects of finasteride on prostate tissue composition.

L S Marks1, A W Partin, F J Dorey, G J Gormley, J I Epstein, J B Garris, M L Macairan, E D Shery, P B Santos, E Stoner, J B deKernion.   

Abstract

OBJECTIVES: To determine the long-term effects of finasteride treatment on prostate tissue composition; to relate these effects to clinical outcomes; and to test the hypothesis that finasteride exerts a selective or preferential action on the transition zone.
METHODS: Nineteen men with symptomatic benign prostatic hyperplasia (BPH) who completed a 6-month double-blind trial of finasteride were enrolled in a 24-month open-label extension study of drug responders. Magnetic resonance imaging and prostate biopsy for morphometric analysis were performed together 70 times: at baseline (n = 19), after treatment periods of intermediate duration (6 to 18 months, n = 32), and after long-term drug treatment (24 to 30 months, n = 19). At baseline, prostate volume averaged 51 cc, of which 57% was transition zone.
RESULTS: Decreases in symptom score, dihydrotestosterone and prostate-specific antigen levels, and prostate volume occurred at 6 months (P <0.01), stabilized, and were maintained without further long-term decreases. Prostate epithelium contracted progressively from baseline (19.2% tissue composition; 6.0-cc volume; 3.2 stroma/epithelial ratio) to intermediate (12.5%, 3.3 cc, and 5.6, respectively) to long-term treatment (6.4%, 2.0 cc, and 17.4, respectively, P <0.01 for all). Percent epithelial contraction was similar in the peripheral and transition zones (P = NS). The transition zone remained a relatively constant proportion (53% to 58%) of whole-prostate volume from baseline to long-term observation.
CONCLUSIONS: Long-term finasteride treatment (24 to 30 months) results in a marked involution of the prostate epithelium, which continues to progress for many months after clinical effects stabilize. The effect on the epithelium is similar in the peripheral and transition zones for both morphometric and volumetric changes. Progressive contraction of the prostate epithelium appears to constitute the underlying mechanism for sustained action of finasteride.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096387

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  18 in total

Review 1.  Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.

Authors:  Vincent M Santillo; Franklin C Lowe
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease.

Authors:  Leonard S Marks
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

3.  MRI characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal volumes.

Authors:  Hong Truong; Jennifer Logan; Baris Turkbey; M Minhaj Siddiqui; Soroush Rais-Bahrami; Anthony N Hoang; Chad Pusateri; Brian Shuch; Annerleim Walton-Diaz; Srinivas Vourganti; Jeffrey Nix; Lambros Stamatakis; Colette Harris; Celene Chua; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Can J Urol       Date:  2013-12       Impact factor: 1.344

Review 4.  Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia.

Authors:  Brian Garvey; Barış Türkbey; Hong Truong; Marcelino Bernardo; Senthil Periaswamy; Peter L Choyke
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

5.  5alpha-reductase: history and clinical importance.

Authors:  Leonard S Marks
Journal:  Rev Urol       Date:  2004

6.  The Clinical Benefits of Dutasteride Treatment for LUTS and BPH.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2004

7.  The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.

Authors:  Steffen E Eikenberry; John D Nagy; Yang Kuang
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

Review 8.  An introduction to acinar pressures in BPH and prostate cancer.

Authors:  Panikar Wadhera
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

Review 9.  Hypertension, RAS, and gender: what is the role of aminopeptidases?

Authors:  María Jesús Ramírez-Expósito; José Manuel Martínez-Martos
Journal:  Heart Fail Rev       Date:  2008-01-24       Impact factor: 4.214

10.  5α-Reductase Isozymes in the Prostate.

Authors:  Yuan-Shan Zhu; Guang-Huan Sun
Journal:  J Med Sci       Date:  2005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.